160 related articles for article (PubMed ID: 37690321)
1. AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
Zhao D; Zhou Q; Zarif M; Eladl E; Wei C; Atenafu EG; Schuh A; Tierens A; Yeung YWT; Minden MD; Chang H
Leuk Res; 2023 Nov; 134():107376. PubMed ID: 37690321
[TBL] [Abstract][Full Text] [Related]
2. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.
Zhou Q; Zhao D; Zarif M; Davidson MB; Minden MD; Tierens A; Yeung YWT; Wei C; Chang H
Blood Adv; 2024 Apr; 8(7):1760-1771. PubMed ID: 38286462
[TBL] [Abstract][Full Text] [Related]
3. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotype distinctions of CEBPA mutation subtypes in acute myeloid leukemia.
Liu Q; Qi L; Yang M; Zhang X; Li F; Wei H; Wang J
Int J Lab Hematol; 2023 Oct; 45(5):743-750. PubMed ID: 37334560
[TBL] [Abstract][Full Text] [Related]
5. Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
Chen X; Yuan L; Zhang Y; Wang F; Ma X; Fang J; Cao P; Liu Y; Liu Z; Liu M; Chen J; Zhou X; Liu M; Jin D; Wang T; Lu P; Liu H
Am J Hematol; 2024 May; 99(5):824-835. PubMed ID: 38321864
[TBL] [Abstract][Full Text] [Related]
6. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
Kansal R
Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
[TBL] [Abstract][Full Text] [Related]
7. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations.
Tien FM; Yao CY; Tsai XC; Lo MY; Chen CY; Lee WH; Lin CC; Kuo YY; Peng YL; Tseng MH; Wu YS; Liu MC; Lin LI; Chuang MK; Ko BS; Yao M; Tang JL; Chou WC; Hou HA; Tien HF
Blood Cancer J; 2024 Jan; 14(1):15. PubMed ID: 38253683
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
Miyashita N; Onozawa M; Yoshida S; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Fujisawa S; Mori A; Ota S; Kakinoki Y; Tsutsumi Y; Yamamoto S; Miyagishima T; Nagashima T; Ibata M; Wakasa K; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Kondo T; Teshima T
Int J Hematol; 2023 Jul; 118(1):36-46. PubMed ID: 36853451
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi JA; Stasik S; Kramer M; Meggendorfer M; Röllig C; Haferlach T; Valk P; Linch D; Herold T; Duployez N; Taube F; Middeke JM; Platzbecker U; Serve H; Baldus CD; Muller-Tidow C; Haferlach C; Koch S; Berdel WE; Woermann BJ; Krug U; Braess J; Hiddemann W; Spiekermann K; Boertjes EL; Hills RK; Burnett A; Ehninger G; Metzeler K; Rothenberg-Thurley M; Dufour A; Dombret H; Pautas C; Preudhomme C; Fenwarth L; Bornhäuser M; Gale R; Thiede C
Leukemia; 2024 Feb; 38(2):281-290. PubMed ID: 38228680
[TBL] [Abstract][Full Text] [Related]
11. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
[TBL] [Abstract][Full Text] [Related]
12. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
13. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
Bacher U; Schnittger S; Macijewski K; Grossmann V; Kohlmann A; Alpermann T; Kowarsch A; Nadarajah N; Kern W; Haferlach C; Haferlach T
Blood; 2012 May; 119(20):4719-22. PubMed ID: 22442349
[TBL] [Abstract][Full Text] [Related]
14. Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia.
Wang T; Hua H; Wang Z; Wang B; Cao L; Qin W; Wu P; Cai X; Chao H; Lu X
Hematology; 2022 Dec; 27(1):994-1002. PubMed ID: 36066283
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Wakita S; Sakaguchi M; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Tajika K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Kayamori K; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Kurosawa A; Mizoguchi A; Komatsu N; Fukuda T; Ohashi K; Kanda Y; Inokuchi K; Yamaguchi H
Blood Adv; 2022 Jan; 6(1):238-247. PubMed ID: 34448807
[TBL] [Abstract][Full Text] [Related]
19. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.
Pabst T; Eyholzer M; Fos J; Mueller BU
Br J Cancer; 2009 Apr; 100(8):1343-6. PubMed ID: 19277035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]